Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.80 |
| ▸ | TTR | P02766 | 1/20 | 0.80 |
| ▸ | ALB | P02768 | 1/20 | 0.80 |
| ▸ | CNR1 | P21554 | 1/20 | 0.80 |
| ▸ | DRD1 | P21728 | 1/20 | 0.80 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.54 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11560388 | 0.89 | MAPT (0.65) | MAOATTRALBCNR1DRD1 | |
| Tafamidis SCHEMBL29361223 | 0.89 | TTR (1.00) | MAOATTRALBCNR1DRD1 | |
| Tafamidis SCHEMBL442508 | 0.89 | TTR (1.00) | MAOATTRALBCNR1DRD1 | |
| Tafamidis SCHEMBL25398819 | 0.87 | TTR (0.97) | MAOATTRALBCNR1DRD1 | |
| SCHEMBL9797021 | 0.86 | HDAC6 (0.65) | MAOATTRALBCNR1DRD1 | |
| SCHEMBL13135790 | 0.85 | HDAC6 (0.63) | MAOATTRALBCNR1DRD1 | |
| SCHEMBL445014 | 0.84 | HDAC6 (0.74) | MAOATTRALBCNR1DRD1 | |
| Hydrochloric Acid SCHEMBL17985190 | 0.84 | HDAC6 (0.62) | MAOATTRALBCNR1DRD1 | |
| SCHEMBL1675367 | 0.83 | CASP3 (0.68) | MAOATTRALBCNR1DRD1 | |
| SCHEMBL440152 | 0.83 | TTR (0.56) | MAOATTRALBCNR1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587821-B1 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | SCRIPPS RESEARCH INST (US) | 2008-08-20 | — | — | EP | claimed |
| US-7214696-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | claimed |
| US-7214695-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | claimed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | claimed |
| EP-4637706-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF TAFAMIDIS | TAP Pharmaceuticals AG (CH) | 2025-10-29 | — | — | EP | disclosed |
| US-12268669-B2 | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent | PFIZER INC. (US) | 2025-04-08 | — | — | US | disclosed |
| WO-2024133874-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF TAFAMIDIS | TAP PHARMACEUTICALS AG (CH) | 2024-06-27 | — | — | WO | disclosed |
| US-11980685-B1 | Liquid pharmaceutical formulations of tafamidis | TAP PHARMACEUTICALS, AG (CH) | 2024-05-14 | — | — | US | disclosed |
| US-20220071965-A1 | Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent | PFIZER INC. (US) | 2022-03-10 | — | — | US | disclosed |
| WO-2020128816-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF A BENZOXAZOLE TRANSTHYRETIN STABILIZER AND AN ADDITIONAL THERAPEUTIC AGENT | PFIZER INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2325651-B1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140134753-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-15 | — | — | US | disclosed |
| EP-1587821-A4 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | SCRIPPS RESEARCH INST (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7214696-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214695-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | disclosed |
| EP-1587821-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | The Scripps Research Institute (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040152140-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE | 2004-08-05 | — | — | US | disclosed |
| WO-2004056315-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | TTR, TTPA, PRNP | MAOA 1980/4885TTR 1/4885ALB 26/4885 |
| US-20220071965-A1 | Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent | TTR, TTPA, GBA1 | MAOA 797/4885TTR 1/4885ALB 4/4885 |
| US-12268669-B2 | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent | TTR, TTPA, GBA1 | MAOA 797/4885TTR 1/4885ALB 4/4885 |
| US-11980685-B1 | Liquid pharmaceutical formulations of tafamidis | TAF11, TAF1, TAF5 | MAOA 2347/4885TTR 141/4885ALB 1374/4885 |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | TTR, TTPA, PRNP | MAOA 2954/4885TTR 1/4885ALB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.